BD Enters NGS Market
GenCell released the CLiC library-preparation system this year (see IBO 4/30/14). The firm has 67 employees, according to BD. A BD spokesperson told IBO that it would focus on both research and diagnostic applications of the technology. “We believe that this opportunity aligns with our significant experience in sample collection/preparation and our ability to bring products from research to clinical markets,” the spokesperson said.
Franklin Lakes, NJ 10/13/14—Becton, Dickinson and Company (BD) has acquired GenCell Biosystems for an undisclosed amount. Founded in 2011 and based in Ireland with an office in the US, GenCell provides technology for biological-analysis protocols, including library preparation for next-generation sequencing (NGS) and genotyping for agricultural applications. “We are excited with the GenCell Biosystems acquisition as it provides BD entry into the NGS market, a fast-growing segment with the potential to have a significant impact on health care,” stated BD Group President Linda Tharby. “The acquisition gives BD access to the NGS market with a differentiated platform that will provide a base to further grow our genomics offerings.”
